Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skeletal muscle-derived cell implantation for fecal incontinence (dose-finding)
2010-021463-32Phase 2Terminated
- Sponsor
- Innovacell
- Start
- Nov 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous skeletal muscle-derived cells in fecal incontinence (FI) (4 arms), sponsored by Innovacell. Primary endpoint: Frequency of incontinence episodes (Day -28 to Day 180). Started Nov 2010; status: terminated.
02
Drugs
autologous skeletal muscle-derived cells
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on 2010-021463-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021463-32.